CAND1

Across TCGA pan-cancer cohorts, CAND1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CAND1 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CAND1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CAND1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where CAND1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	15	view →
HNSC	DFS	Median	All	0.361	0.895	.007	15	view →
PDAC	OS	Quartile	II,III,IV	0.678	0.950	.009	14	view →
GBM	OS	Quartile	All	0.247	0.611	.025	4	view →
LUAD	OS	Quartile	All	0.560	0.952	.013	4	view →
UCEC	OS	Tertile	All	0.898	1.000	.018	4	view →
LSCC	DFS	Median	All	0.966	0.911	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CAND1–CCRCC (OS)

Open the CCRCC breakdown →